ASPEN, SAUDI CHEMICAL COMPANY HOLDING AND ITS SUBSIDIARY AJA PHARMA ENTER INTO A MEMORANDUM OF UNDERSTANDING

Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational pharmaceutical company, has entered into a memorandum of understanding (“MOU”) with Saudi Chemical Company Holding (“SCCH”), a well-known company in the local market of the Kingdom of Saudi Arabia, and its subsidiary AJA Pharmaceutical Industries Ltd (“AJA Pharma”), a recognized manufacturer of pharmaceutical products.

In terms of this MOU, Aspen, SCCH and AJA Pharma will further expand their existing partnership to strategically collaborate on an extended portfolio of products, the manufacturing of products in the Kingdom of Saudi Arabia, and the export of products to existing Aspen markets.

Daniel Vella Friggieri, Aspen Healthcare Regional CEO for Middle East, North Africa & Turkey, said, “We are excited to announce our strategic collaboration with Saudi Chemical Company Holding and its subsidiary AJA Pharma. This agreement endorses Aspen’s continuous commitment to align with the Kingdom’s 2030 vision and our drive to provide high quality healthcare products to patients in the Kingdom, the Middle East region and beyond”.

Thamer Almuhid, Saudi Chemical Company Holding Group CEO commented, “Nowadays technology and globalization play a more important role than ever; having a strategic partnership between Aspen and AJA Pharma will ensure that both the aspects of technologies and global market access are fulfilled towards achieving the KSA 2030 vision. We are pleased to partner with a trusted partner like Aspen and look forward to a prosperous strategic partnership”.

About Aspen

Headquartered in Durban, South Africa, Aspen is a leading global specialty and branded multinational pharmaceutical company in both emerging and developed markets.

Aspen improves the health of patients in more than 115 countries through its high quality, affordable and effective healthcare solutions. The Group’s key business segments are Manufacturing and Commercial Pharmaceuticals comprising Regional Brands and Sterile Focus Brands that include anaesthetics and thrombosis products.

Aspen employs more than 9 000 people and has 69 established offices in over 50 countries. The Group operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. Its manufacturing capabilities that are scalable to demand and cover a wide variety of product-types including steriles, oral solid dose, liquids, semi-solids, biologicals, and active pharmaceutical ingredients.

For more information visit www.aspenpharma.com

Disclaimer

We may make statements that are not historical facts and relate to analyses and other information based on forecasts of future results and estimates of amounts not yet determinable. These are forward-looking statements as defined in the U.S. Private Securities Litigation Reform Act of 1995. Words such as “prospects”, “believe”, “anticipate”, “expect”, “intend”, “seek”, “will”, “plan”, “indicate”, “could”, “may”, “endeavour” and “project” and similar expressions are intended to identify such forward-looking statements but are not the exclusive means of identifying such statements. By their very nature, forward looking statements involve inherent risks and uncertainties, both general and specific, and there are risks that predictions, forecasts, projections, and other forward-looking statements will not be achieved. If one or more of these risks materialise, or should underlying assumptions prove incorrect, actual results may be very different from those anticipated. The factors that could cause our actual results to differ materially from the plans, objectives, expectations, estimates, and intentions expressed in such forward-looking statements are discussed in each year’s annual report. Forward looking statements apply only as of the date on which they are made, and we do not undertake other than in terms of the Listings Requirements of the JSE Limited, any obligation to update or revise any of them, whether as a result of new information, future events or otherwise. Any profit forecasts published in this report are unaudited and have not been reviewed or reported on by Aspen’s external auditors.

About Saudi Chemical Company Holding

Saudi Chemical Company Holding (SCCH), is a listed company that owns and manages diversified investments to contribute to Saudi Arabia’s development process. It is a leading provider of pharmaceutical manufacturing and marketing services in the Kingdom through its pharmaceutical sector subsidiaries.

About AJA Pharmaceutical Industries Ltd.

AJA Pharma has a Pharmaceutical Manufacturing site in Ha’il, Saudi Arabia. AJA’s plant is built to provide a wide range of pharmaceutical products in various finished dosage forms for different therapeutic classes, according to the latest approved research and development results as provided through successful business models with our worldwide known partners. Also, relying on the huge capabilities, highest quality, and unique technologies we have in AJA site, the site will produce Sterile injectables (Liquid & Lyophilized) to satisfy the ever-increasing market demands in the specialized therapy areas. Our goal to always be the partner of choice, in order to provide the best, not only for our customers, but also the best for the society, the industry and for the environment seeking to realize Kingdom’s Vision 2030 of healthcare and pharmaceutical industries.